Human umbilical cord mesenchymal stem cell therapy (Beijing Sh Biotechnology/Capital Medical University)

人牙髓间充质干细胞（北京三有利和泽生物/首都医科大学）

Report date: 2023/05/30 20:00:25

Base Information

Drug NameHuman umbilical cord mesenchymal stem cell therapy (Beijing Sh Biotechnology/Capital Medical University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Source of cells > Dental pulp-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Chronic Periodontitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Sh Biotechnology Co LtdCapital Medical University
China Registration ClassN/A

Develop Information

Active CompaniesCapital Medical UniversityBeijing Sh Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic Periodontitis
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A